Omalizumab, an anti-IgE monoclonal antibody, has been reported to be effective in reducing the systemic side effects of subcutaneous immunotherapy for inhaled allergen in pollen-induced allergic rhinitis, mild–moderate allergic asthma, and venom allergy [9]. The gene discussed is IGHE; the disease is allergic rhinitis.